Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Johnson & Johnson reports 9.1% increase in sales for Q4 2025
For the entire year, sales grew by 6% to $94.2bn, and full-year earnings per share (EPS) registered at $11.03. The diluted earnings per share (EPS) for Q4 2025
For the entire year, sales grew by 6% to $94.2bn, and full-year earnings per share (EPS) registered at $11.03. The diluted earnings per share (EPS) for Q4 2025
The International Nonproprietary Names (INN) approved the generic name zavabresib for OPN-2853. Myelofibrosis is a rare blood cancer involving bone marrow scarring, resulting in anaemia, severe fatigue, ineffective
The collaboration will deploy radiology AI algorithms cleared by the US Food and Drug Administration (FDA) through Microsoft’s Precision Imaging Network, a component of its healthcare radiology solutions.
The collaboration, which began in 2023, aims to create therapies that can replace, repair, or supplement biological functions in patients, advancing the development of disease-modifying treatments. Under the
The new solution is intended for pharmaceutical and medical device manufacturers, enabling them to train operators, guide execution, and verify critical tasks using advanced AI-technologies. Pharmaceutical manufacturers frequently
This marks the first instance of an allogeneic induced pluripotent stem cell (iPSC)-derived cell therapy receiving both fast track and RMAT designations from the FDA, with the former
The acquisition gives AstraZeneca full global control over the development, manufacturing, and commercialisation of the therapy. AbelZeta will receive up to $630m from AstraZeneca, including upfront payments and
Ianalumab is a fully human monoclonal antibody that targets B-cells and inhibits their activation and survival by blocking B-cell activating factor receptor (BAFF-R). Novartis intends to submit ianalumab
Financial details of the transaction have not been disclosed. The partnership aims to deliver durable weight loss with improved tolerability, focusing on a target and modality of established
The collaboration secures funding and sustained biologics manufacturing capacity in the US for Agenus, supporting clinical development, early access initiatives, and future commercial production. Under the agreement, Agenus